Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • AstraZeneca, Shionogi endocrine/metabolic news

    AstraZeneca plc (LSE:AZN; NYSE: AZN), London, U.K. Shionogi & Co. Ltd., (Tokyo:4507), Osaka Japan Business: Endocrine/Metabolic The U.S. District Court for the District of Columbia denied a motion from AstraZeneca …

    Published on 7/25/2016
  • Foundation Medicine, National Cancer Institute genomics news

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. National Cancer Institute, Bethesda, Md. Business: Genomics Foundation Medicine is donating 18,000 genomic profiles of adult cancers to National Cancer Institutes …

    Published on 7/25/2016
  • Zafgen endocrine/metabolic news

    Zafgen Inc. (NASDAQ:ZFGN), Cambridge, Mass. Business: Endocrine/Metabolic Zafgen will reduce headcount by 47 (34%) to 31 and discontinue development of beloranib (ZGN-440) to focus on developing ZGN-1061 to treat severe…

    Published on 7/25/2016
  • Avita, U.S. Department of Health and Human Services dermatology, gene/cell therapy news

    Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY), Perth, Australia U.S. Department of Health and Human Services, Washington, D.C. Business: Dermatology, Gene/Cell therapy HHSs Biomedical Advanced Research and Development …

    Published on 7/18/2016
  • Amgen, Apotex hematology, biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Apotex Inc., Toronto, Ontario Business: Hematology, Biosimilars The U.S. Court of Appeals for the Federal Circuit (CAFC) upheld a lower court ruling granting Amgen a …

    Published on 7/11/2016
  • Arena gastrointestinal, cardiovascular, neurology news

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Business: Gastrointestinal, Cardiovascular, Neurology Arena will reduce U.S. headcount by about 100 (73%) to about 37 to reduce costs and focus on its clinical…

    Published on 7/11/2016
  • BioBlast Pharma musculoskeletal news

    BioBlast Pharma Ltd. (NASDAQ:ORPN), Tel Aviv, Israel Business: Musculoskeletal BioBlast is reducing headcount by 8 (40%) to 12 and will focus development on 90 mg/mL IV trehalose (formerly Cabaletta). The cuts include …

    Published on 7/11/2016
  • Eleven Biotherapeutics ophthalmic news

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Business: Ophthalmic Eleven Biotherapeutics said it will reduce headcount by 14 (70%) to about six. This month, FDA approved an IND for EBI-031 to treat ocular…

    Published on 7/11/2016
  • Emergent BioSolutions, U.S. Department of Health and Human Services infectious news

    Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) granted …

    Published on 7/11/2016
  • Fibrocell dermatology, autoimmune news

    Fibrocell Science Inc. (NASDAQ:FCSC), Exton, Pa. Business: Dermatology, Autoimmune Fibrocell reduced headcount by 24 (about 50%) to about 24 and will wind down its azficel-T operations after the candidate missed the …

    Published on 7/11/2016
  • GlaxoSmithKline, FNIH, National Cancer Institute, NIH, U.S. Department of Energy cancer news

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Foundation for the National Institutes of Health, Bethesda, Md National Cancer Institute, Bethesda, Md. National Institutes of Health, Bethesda, Md. U.S. Department …

    Published on 7/11/2016
  • Infinity cancer news

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. Business: Cancer Infinity announced two restructurings in June to reduce headcount by a total of 146 (69%) to 65. Under the first, the company eliminated 46 …

    Published on 7/11/2016
  • Mologen cancer, infectious news

    Mologen AG (Xetra:MGN), Berlin, Germany Business: Cancer, Infectious Mologen will reduce headcount by 17 (26%) to 49 and focus on developing lead product lefitolimod (MGN1703), a toll-like receptor 9 (TLR9) agonist …

    Published on 7/11/2016
  • Natera, Sequenom, Thermo Fisher, Roche diagnostic news

    Natera Inc. (NASDAQ:NTRA), San Carlos, Calif. Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic…

    Published on 7/11/2016
  • Pfizer biosimilars news

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Biosimilars Pfizer is investing about $350 million to build the Pfizer Global Biotechnology Center in Hangzhou, China. The center, Pfizers first in Asia, will focus on …

    Published on 7/11/2016
  • Terumo, U.S. Department of Health and Human Services hematology news

    Terumo Corp. (Tokyo:4543), Tokyo, Japan U.S. Department of Health and Human Services, Washington, D.C. Business: Hematology HHSs Biomedical Advanced Research and Development Authority (BARDA) awarded Terumos Terumo BCT …

    Published on 7/11/2016
  • Achaogen, U.S. Department of Health and Human Services infectious news

    Achaogen Inc. (NASDAQ:AKAO), South San Francisco, Calif. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) exercised…

    Published on 6/27/2016
  • Chiasma endocrine/metabolic news

    Chiasma Inc. (NASDAQ:CHMA), Waltham, Mass. Business: Endocrine/Metabolic Chiasma will reduce headcount by about 33% after FDA issued a complete response letter in April to an NDA for Mycapssa octreotide (RG3806) as a …

    Published on 6/27/2016
  • Novartis biosimilars news

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars Novartis Sandoz Inc. unit said it plans to launch five biosimilars worldwide by 2020. The planned launches include GP2015, a biosimilar of …

    Published on 6/27/2016
  • Semma Therapeutics, Brigham and Womens Hospital, Dana-Farber Cancer Institute, Harvard, Joslin Diabetes Center endocrine/metabolic news

    Semma Therapeutics Inc., Cambridge, Mass. Brigham and Womens Hospital, Boston, Mass. Dana-Farber Cancer Institute, Boston, Mass. Harvard University, Cambridge, Mass. Joslin Diabetes Center, Boston, Mass. Business: …

    Published on 6/27/2016
  • Atox Bio, U.S. Department of Health and Human Services infectious news

    Atox Bio Inc., Ness Ziona, Israel U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) exercised an option under a 2014 …

    Published on 6/20/2016
  • Medivir infectious, neurology, musculoskeletal news

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Infectious, Neurology, Musculoskeletal Medivirs board tasked management to consider dividing the company into two independent companies: an R&D company and a …

    Published on 6/20/2016
  • Gilead, Ionis Pharmaceuticals, Merck infectious news

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious A federal judge reversed a …

    Published on 6/13/2016
  • Catalyst Pharmaceuticals autoimmune news

    Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Coral Gables, Fla. Business: Autoimmune Catalyst reduced headcount by about 30% to conserve cash to complete requirements for an NDA submission for Firdapse amifampridine …

    Published on 6/6/2016
  • Neuralstem neurology news

    Neuralstem Inc. (NASDAQ:CUR), Rockville, Md. Business: Neurology Neuralstem will reduce headcount across all divisions to focus on developing NSI-189 and pursuing partnerships for NSI-566. NSI-189, a small molecule …

    Published on 6/6/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993